Sarilumab (NCT05428007)

Name: Sarilumab trial for Melanoma (NCT05428007)
Uploaded: 2026-10-31T05:30:36.842Z
Duration: 1 min 21 s
Description: Sarilumab trial for Melanoma (NCT05428007). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05428007.

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma: a one-minute explainerNCT054280071 min

Sarilumab trial for Melanoma (NCT05428007). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults aged 18–100 with unresectable stage IIIb–d or IV melanoma, excluding ocular melanoma. Prior treatment for metastatic disease is restricted; some surgery, radiation and adjuvant treatments are allowed.

The idea: test sarilumab with ipilimumab, nivolumab and relatlimab. Sarilumab blocks IL-6 inflammation signaling; the other drugs release immune brakes. After an initial four-drug stage, a randomized stage compares the combination with or without sarilumab, measuring serious immune side effects and tumor response.

This phase 2 study plans 105 patients. NYU Langone leads; four US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.